Pasar al contenido principal

MODULACION DE LOS HETEROMEROS DE RECEPTORES ACOPLADOS A PROTEINAS G POR LIGANDOS Y PROTEINAS

PID2019-109240RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Orally active peptide vector allows using cannabis to fight pain while avoiding side effects

  • Gallo, María, 1989-
  • Moreno, Estefanía
  • Defaus, Sira
  • Ortega Alvaro, Antonio
  • Gonzalez, Angel
  • Robledo, Patricia, 1958-
  • Cavaco, Marco
  • Neves, Vera
  • Castanho, Miguel A.R.B.
  • Casadó, Vicent
  • Pardo Carrasco, Leonardo
  • Maldonado, Rafael, 1961-
  • Andreu Martínez, David
The activation of cannabinoid CB1 receptors (CB1R) by Δ9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CB1R activation, however, also causes cognitive impairment via the serotonin 5HT2A receptor (5HT2AR), a component of a CB1R-5HT2AR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CB1R transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CB1R-5HT2AR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CB1R-5HT2AR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood-brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia., Rhodes Pharmaceuticals (L.P., Coventry, R.I., USA; 2016–2017), Marie Skłodowska-Curie Research and Innovation Staff Exchange (call H2020-MSCA-RISE-2014, 2015–2019), the Spanish Ministry of Economy and Innovation with FEDER funds (SAF2017-87629-R, PID2019-109240RB-I00), and the Fundació Bancària La Caixa (CaixaImpulse 2018 call; 2018–2020).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor

  • Morales, Paula
  • Navarro, Gemma
  • Gómez-Autet, Marc
  • Redondo, Laura
  • Fernández-Ruiz, Javier
  • Pérez-Benito, Laura
  • Cordomí, Arnau
  • Pardo, Leonardo
  • Franco, Rafael
  • Jagerovic, Nadine
Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in medicinal chemistry. We have designed, synthesized and functionally characterized the first bitopic ligands for the CB2 receptor. These compounds selectively target CB2 versus CB1 receptors. Their binding mode was studied by molecular dynamic simulations and site¿directed mutagenesis., This work was supported by the MICIU/FEDER (RTI2018- 095544-B-I00, PID2019-109240RB-I00, SAF2017-84117-R), and by the CSIC (PIE-201580E033). P.M. is grateful to the CM program “Atraccijn de Talento Investigador” number 2018-T2/ BMD-1081.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Orally active peptide vector allows using cannabis to fight pain while avoiding side effects

  • Gallo, María, 1989-
  • Moreno, Estefanía
  • Defaus, Sira
  • Ortega Alvaro, Antonio
  • Gonzalez, Angel
  • Robledo, Patricia, 1958-
  • Cavaco, Marco
  • Neves, Vera
  • Castanho, Miguel A.R.B.
  • Casadó, Vicent
  • Pardo Carrasco, Leonardo
  • Maldonado, Rafael, 1961-
  • Andreu Martínez, David
The activation of cannabinoid CB1 receptors (CB1R) by Δ9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CB1R activation, however, also causes cognitive impairment via the serotonin 5HT2A receptor (5HT2AR), a component of a CB1R-5HT2AR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CB1R transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CB1R-5HT2AR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CB1R-5HT2AR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood-brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia., Rhodes Pharmaceuticals (L.P., Coventry, R.I., USA; 2016–2017), Marie Skłodowska-Curie Research and Innovation Staff Exchange (call H2020-MSCA-RISE-2014, 2015–2019), the Spanish Ministry of Economy and Innovation with FEDER funds (SAF2017-87629-R, PID2019-109240RB-I00), and the Fundació Bancària La Caixa (CaixaImpulse 2018 call; 2018–2020).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB Receptor

  • Morales, Paula|||0000-0002-6209-8600
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gómez-Autet, Marc|||0000-0002-6133-988X
  • Redondo, Laura
  • Fernández-Ruiz, Javier|||0000-0002-4490-0604
  • Pérez-Benito, Laura|||0000-0001-9607-9048
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Franco, Rafael|||0000-0003-2549-4919
  • Jagerovic, Nadine|||0000-0003-2642-6969
Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in medicinal chemistry. We have designed, synthesized and functionally characterized the first bitopic ligands for the CB receptor. These compounds selectively target CB versus CB receptors. Their binding mode was studied by molecular dynamic simulations and site-directed mutagenesis. Single chemical entities with potential to simultaneously interact with two binding sites are emerging strategies in GPCR pharmacology. We present herein the design, synthesis and functional characterization of the first bitopic ligands for the CB receptor. Molecular understanding of the binding mode was guided by molecular dynamic simulations and site-directed mutagenesis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease

  • Franco, Rafael|||0000-0003-2549-4919
  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
  • Casanovas, Mireia
  • Lillo, Alejandro
  • Saura Antolín, Carlos|||0000-0003-3692-5657
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
(1) Background. N-methyl d-aspartate (NMDA) ionotropic glutamate receptor (NMDAR), which is one of the main targets to combat Alzheimer's disease (AD), is expressed in both neurons and glial cells. The aim of this paper was to assess whether the adenosine A2A receptor (A2AR), which is a target in neurodegeneration, may affect NMDAR functionality. (2) Methods. Immuno-histo/cytochemical, biophysical, biochemical and signaling assays were performed in a heterologous cell expression system and in primary cultures of neurons and microglia (resting and activated) from control and the APPSw,Ind transgenic mice. (3) Results. On the one hand, NMDA and A2A receptors were able to physically interact forming complexes, mainly in microglia. Furthermore, the amount of complexes was markedly enhanced in activated microglia. On the other hand, the interaction resulted in a novel functional entity that displayed a cross-antagonism, that could be useful to prevent the exacerbation of NMDAR function by using A2AR antagonists. Interestingly, the amount of complexes was markedly higher in the hippocampal cells from the APPSw,Ind than from the control mice. In neurons, the number of complexes was lesser, probably due to NMDAR not interacting with the A2AR. However, the activation of the A2AR receptors resulted in higher NMDAR functionality in neurons, probably by indirect mechanisms. (4) Conclusions. A2AR antagonists such as istradefylline, which is already approved for Parkinson's disease (Nouriast® in Japan and Nourianz® in the US), have potential to afford neuroprotection in AD in a synergistic-like fashion. i.e., via both neurons and microglia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects

  • Gallo, Maria|||0000-0001-9099-7235
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Defaus, Sira|||0000-0002-3106-458X
  • Ortega-Alvaro, Antonio
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Robledo, Patricia
  • Cavaco, Marco|||0000-0002-0938-9038
  • Neves, Vera|||0000-0002-2989-7208
  • Castanho, Miguel A. R. B.|||0000-0001-7891-7562
  • Casadó, Vicent|||0000-0002-1764-3825
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Maldonado, Rafael|||0000-0002-4359-8773
  • Andreu Martínez, David|||0000-0002-6317-6666
The activation of cannabinoid CB receptors (CBR) by Δ 9 -tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CBR activation, however, also causes cognitive impairment via the serotonin 5HT receptor (5HTR), a component of a CBR-5HTR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CBR transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CBR-5HTR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CBR-5HTR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood-brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB Receptor via the Lipid Bilayer

  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Gómez-Autet, Marc|||0000-0002-6133-988X
  • Quintana García, Aleix|||0000-0003-4472-5129
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
Molecular dynamic (MD) simulations have become a common tool to study the pathway of ligand entry to the orthosteric binding site of G protein-coupled receptors. Here, we have combined MD simulations and site-directed mutagenesis to study the binding process of the potent JWH-133 agonist to the cannabinoid CB receptor (CBR). In CBR, the N-terminus and extracellular loop 2 fold over the ligand binding pocket, blocking access to the binding cavity from the extracellular environment. We, thus, hypothesized that the binding pathway is a multistage process consisting of the hydrophobic ligand diffusing in the lipid bilayer to contact a lipid-facing vestibule, from which the ligand enters an allosteric site inside the transmembrane bundle through a tunnel formed between TMs 1 and 7 and finally moving from the allosteric to the orthosteric binding cavity. This pathway was experimentally validated by the Ala282 7.36 Phe mutation that blocks the entrance of the ligand, as JWH-133 was not able to decrease the forskolin-induced cAMP levels in cells expressing the mutant receptor. This proposed ligand entry pathway defines transient binding sites that are potential cavities for the design of synthetic modulators.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design of negative and positive allosteric modulators of the cannabinoid CB2 Receptor derived from the natural product cannabidiol

  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Sánchez-Morales, Adrià|||0000-0002-8692-0988
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Gómez-Ventura, Marc
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Busqué, Félix|||0000-0001-7566-4264
  • Alibés, Ramon|||0000-0002-7997-2691
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Franco, Rafael|||0000-0003-2549-4919
Cannabidiol (CBD), the second most abundant of the active compounds found in the Cannabis sativa plant, is of increasing interest because it is approved for human use and is neither euphorizing nor addictive. Here, we design and synthesize novel compounds taking into account that CBD is both a partial agonist, when it binds to the orthosteric site, and a negative allosteric modulator, when it binds to the allosteric site of the cannabinoid CB2 receptor. Molecular dynamic simulations and site-directed mutagenesis studies have identified the allosteric site near the receptor entrance. This knowledge has permitted to perform structure-guided design of negative and positive allosteric modulators of the CB2 receptor with potential therapeutic utility.